DERMATOLOGY AND THERAPY : Impact Factor & More
eISSN: 2190-9172pISSN: 2193-8210
Open AccessShare this on:
Key Metrics
H-Index 
38
Scite Index
0.91 5-Year SI
SJR
Q1Dermatology
Recommended pre-submission checks
Powered by 
Run standard language and technical checks to improve your manuscript – before you submit
Technical Compliance
Ensure manuscript complies with standard submission guidelines.
Language Quality
Improve clarity, grammar, and academic writing style.
A comprehensive report covering all these checks awaits you.
Topics Covered on DERMATOLOGY AND THERAPY
DERMATOLOGY AND THERAPY Journal Specifications
Indexed in the following public directories
Web of Science 
Scopus 
DOAJ 
SJR
| Overview | |
| Publisher | ADIS INT LTD |
| Language | English |
| Frequency | Quarterly |
| Article Processing Charges | EUR 5500 | USD 6850 | GBP 0 |
| Publication Time | 6 |
| Editorial Review Process | Anonymous peer review |
| General Details | |
| Language | English |
| Frequency | Quarterly |
| Publication Start Year | 2011 |
| Publisher URL | Visit website |
| Website URL | Visit website |
| Publication Details | |
| Plagiarism | Visit website |
| Publication Time | 6 |
| Editorial Review Detail | |
| Information for authors | |
| Author instructions | Visit website |
| Copyright Details | Visit website |
| Deposit Policy | Sherpa/Romeo |
| License type | CC BY-NC |
| OA statement | Visit website |
View less
Planning to publish in DERMATOLOGY AND THERAPY ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations
Recently Published Papers in DERMATOLOGY AND THERAPY
Zasocitinib (TAK-279), a Highly Selective Oral TYK2 Inhibitor, Demonstrates Skin Clearance in Patients with Moderate-to-Severe Plaque Psoriasis: Post Hoc Analyses of a Randomized Phase IIb Trial.
- 16 May 2026
- Dermatology and therapy
Machine-Learning-Based Prediction of Long-Term Efficacy of Nemolizumab: PostHoc Analysis of Pooled Data from Two Phase III Clinical Trials.
- 15 May 2026
- Dermatology and therapy
Summary of Research: Apremilast Improves Skin Outcomes in Pediatric Plaque Psoriasis of Shorter Disease Duration: 52-Week Results from the SPROUT Phase3 Trial.
- 14 May 2026
- Dermatology and therapy
Dupilumab Treatment Provides Multidimensional Benefits in Patients with Prurigo Nodularis.
- 13 May 2026
- Dermatology and therapy
Symposium on Hidradenitis Suppurativa Advances 2025 Proceedings.
- 11 May 2026
- Dermatology and therapy
Safety and Effectiveness of Adalimumab for the Treatment of Pyoderma Gangrenosum: A 52-Week Real-World Prospective Observational Study.
- 10 May 2026
- Dermatology and therapy
Zasocitinib (TAK-279), a Highly Selective Oral TYK2 Inhibitor, Demonstrates Skin Clearance in Patients with Moderate-to-Severe Plaque Psoriasis: Post Hoc Analyses of a Randomized Phase IIb Trial.
- 16 May 2026
- Dermatology and therapy
Machine-Learning-Based Prediction of Long-Term Efficacy of Nemolizumab: PostHoc Analysis of Pooled Data from Two Phase III Clinical Trials.
- 15 May 2026
- Dermatology and therapy
Summary of Research: Apremilast Improves Skin Outcomes in Pediatric Plaque Psoriasis of Shorter Disease Duration: 52-Week Results from the SPROUT Phase3 Trial.
- 14 May 2026
- Dermatology and therapy
Dupilumab Treatment Provides Multidimensional Benefits in Patients with Prurigo Nodularis.
- 13 May 2026
- Dermatology and therapy
Symposium on Hidradenitis Suppurativa Advances 2025 Proceedings.
- 11 May 2026
- Dermatology and therapy
Safety and Effectiveness of Adalimumab for the Treatment of Pyoderma Gangrenosum: A 52-Week Real-World Prospective Observational Study.
- 10 May 2026
- Dermatology and therapy
FAQs on DERMATOLOGY AND THERAPY
How long has DERMATOLOGY AND THERAPY been actively publishing? 
What is the publishing frequency of DERMATOLOGY AND THERAPY?
How many articles did DERMATOLOGY AND THERAPY publish last year?
What is the eISSN & pISSN for DERMATOLOGY AND THERAPY?
What is the H Index for DERMATOLOGY AND THERAPY ?
What is the SJR for DERMATOLOGY AND THERAPY?
Who is the publisher of DERMATOLOGY AND THERAPY?
